Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Bioregenx (BRGX) Cash from Operations (2022 - 2025)

Bioregenx's Cash from Operations history spans 4 years, with the latest figure at 69636.0 for Q4 2025.

  • Quarterly results put Cash from Operations at 69636.0 for Q4 2025, up 712.94% from a year ago — trailing twelve months through Dec 2025 was 38972.0 (up 112.02% YoY), and the annual figure for FY2025 was 38972.0, up 112.02%.
  • Cash from Operations for Q4 2025 was 69636.0 at Bioregenx, up from 71564.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 69636.0 in Q4 2025 to a low of 649161.0 in Q2 2023.
  • The 4-year median for Cash from Operations is 32153.0 (2022), against an average of 116554.44.
  • The sharpest move saw Cash from Operations crashed 5528.46% in 2023, then soared 712.94% in 2025.
  • Year by year, Cash from Operations stood at 4364.0 in 2022, then crashed by 5528.46% to 245626.0 in 2023, then skyrocketed by 95.37% to 11361.0 in 2024, then soared by 712.94% to 69636.0 in 2025.
  • According to Business Quant data, Cash from Operations over the past three periods came in at 69636.0, 71564.0, and 3205.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.